What happened with MIR today?
No read yet
Uses news and trading volume to explain the day’s move and how it relates to the market.
Stop guessing. Get the call, a three-month target price, the best and worst cases, and a source for every claim.
Mirion Technologies earns most of its revenue from Nuclear & Safety, supplying equipment that detects and measures radiation to nuclear operators, laboratories, industrial companies and defense organizations. Nuclear plants buy its equipment for construction, operation and eventual decommissioning. Most of its nuclear-power revenue comes from equipment already installed at customers’ plants, which generates repeat replacement and service work throughout their operating lives.
Its Medical business sells hospitals and cancer centers tools to check the accuracy of radiation treatments and imaging, along with equipment for nuclear medicine. Employers also pay Mirion to monitor workers’ radiation exposure and maintain official dose records, using products such as Instadose and the Dose Central data platform. Mirion sells directly and through sales representatives and distributors.
No single customer dominates revenue, but a substantial part of its U.S. business comes from government customers or their contractors and depends on public spending. Mirion and its customers need permits and licenses to operate facilities and handle radioactive materials; certain medical devices also require regulatory approval or registration. These requirements constrain which products it can sell and when customers can use them.
The risk section is the longest, dullest part of the filing. This keeps only what can really hurt you: where it hits, how hard, when it plays out.
Every company claims an edge. Each one is checked against hard numbers like margins and returns: which hold, and which line gives way first.
Curtiss-Wright competes with Mirion to supply technologies critical to nuclear plant safety, so its nuclear business offers a read on Mirion’s largest market. Watch its business with plants maintaining and upgrading equipment: more than 80% of Mirion’s nuclear power end-market revenue comes from its installed base.
BWX Technologies and Mirion serve the same nuclear and medical markets from different sides: BWXT supplies reactors, components and medical isotopes, while Mirion sells radiation measurement and handling equipment. BWXT’s naval and commercial nuclear business and medical isotope sales offer signals of demand in markets Mirion also serves.
Fortive competes with Mirion through Landauer in medical radiation monitoring and through Fluke in nuclear and safety products. Its radiation safety monitoring business is the relevant part to watch for demand and competition in services that record workers’ radiation exposure, rather than Fortive’s overall results.
AMETEK’s Ortec competes with Mirion for nuclear and scientific customers buying instruments to detect and analyze radiation. News about Ortec’s radiation instruments is more directly relevant to Mirion than AMETEK’s broader instrument and component businesses.
Thermo Fisher Scientific competes with Mirion to sell radiation detection and measurement products to nuclear, research and industrial customers. Watch those products rather than its overall results: they make up only a small part of Thermo Fisher’s much broader business.
Teledyne’s FLIR competes with Mirion in detection products for nuclear and safety customers, including defense and industrial users. FLIR’s detection-product news is the closer signal for Mirion; Teledyne also sells a much broader range of imaging systems and instruments.
Cameco and Mirion both serve operating and expanding reactor fleets: Cameco supplies uranium and services that turn it into reactor fuel, while Mirion supplies monitoring equipment. Cameco’s reactor-fuel business is the useful connection to watch, since uranium prices affect Cameco more directly than Mirion.
Mirion Technologies, Inc. earningsThis company
Mirion Technologies, Inc.'s report will show whether customer demand in its Nuclear & Safety and Medical businesses is turning into higher sales and profit.
Read what is driving revenue in each segment alongside its operating profit. If sales grow mainly through higher volumes and segment profit rises too, nuclear-plant, laboratory and medical customers are buying more, and Mirion is turning that demand into earnings. If growth relies mostly on price, acquisitions or currency effects while volumes are weak—or profit fails to keep pace—the demand is narrower or more costly to convert into profit.
Fortive Corporation earningsFTV
Fortive's report on Landauer's radiation-monitoring business will show whether demand for worker-monitoring services, which Mirion also provides, is strengthening or softening.
Look for sales or demand commentary specifically about Landauer's radiation-safety monitoring business, not Fortive's overall results. Stronger sales or demand would suggest customers are continuing to buy worker-monitoring services, a supportive signal for Mirion's dosimetry business. Weaker signals would point to possible pressure on demand for these services, but would not prove Mirion's own sales are falling.
Fed Interest Rate Decision
Mirion’s rate decision matters because it helps set economy-wide borrowing costs, which can change the interest expense on Mirion’s variable-rate term loan and revolving facility.
Expected4.0%Last release4.0%
If it comes in above expectations
If the policy rate is higher than expected, Mirion may pay more interest on its variable-rate debt, leaving less cash for operations, investment or debt repayment.
If it comes in below expectations
If the policy rate is lower than expected, interest costs on Mirion’s variable-rate debt may fall, leaving more cash for operations, investment or debt repayment.
Ametek, Inc. earningsAME
AMETEK's report on Ortec's radiation instruments will show how nuclear and scientific customers are buying in a market where Mirion also sells radiation-measurement products.
Look for sales or demand commentary about Ortec's radiation instruments; AMETEK's overall results are not a substitute for that business. Stronger Ortec-related sales or demand would suggest nuclear and scientific customers are buying more radiation-detection and analysis instruments, supporting demand in a market Mirion serves too. Weaker signals would suggest purchasing may be slowing, but would not prove Mirion's sales are falling.
Curtiss-Wright Corp. earningsCW
Curtiss-Wright's report on nuclear-plant maintenance and upgrades will show whether operators are spending on existing plants, which supports demand for Mirion's installed-base equipment, replacements and services.
Focus on Curtiss-Wright's business or commentary tied to nuclear-plant maintenance and upgrades, not its entire nuclear business. Stronger signals would indicate operators are spending to maintain and upgrade plants, supporting Mirion's replacement and service opportunities across its installed base. Weaker signals could mean spending is delayed or constrained, pushing out some related orders and revenue for Mirion.
